Apellis Pharmaceuticals Appoints Mikael Dolsten to Board of Directors
Apellis Pharmaceuticals (APLS) that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer (PFE), during which he presided over the regulatory approval of more than 36 medicines and vaccines.
